Victory Capital Management
MBRX icon

Victory Capital Management’s Moleculin Biotech MBRX Stock Holding History

Victory Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7
Closed -$10K – 2942
2020
Q1 		$10K Buy
+7
New +$11.9K ﹤0.01% 3299
2019
Q4 		– Sell
-3
Closed -$8K – 2995
2019
Q3 		$8K Buy
+3
New +$7.75K ﹤0.01% 3335

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
WIC
Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management's MBRX Position: Q2 2020 in Review

Victory Capital Management sold out of Moleculin Biotech (MBRX) in Q2 2020, closing a stake of 7 shares — an estimated $10K sold.

Victory Capital Management first reported a position in MBRX in Q3 2019 and held it in 2 quarters. The position peaked at $10K in Q1 2020. 24 funds tracked by Wall St. Rank hold MBRX as of Q2 2020.

  • Victory Capital Management reported no remaining Moleculin Biotech position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 7 Moleculin Biotech shares in Q2 2020, an estimated $10K.
  • Victory Capital Management first reported a position in Moleculin Biotech in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Moleculin Biotech position peaked at $10K in Q1 2020.
  • 24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.